Industry & Policy News

[Ocean Biomedical, Inc. (Globe Newswire)] Ocean Biomedical, Inc. celebrated the discovery of bispecific antibodies that target Chitinase 3-like-1 and immune checkpoint inhibitors, killing glioblastoma cells and melanoma cells, and blocking the metastasis of malignant melanoma cells to the lung by over 90%.

[Roche] Roche announced the launch of the IDH1 R132H Rabbit Monoclonal Primary Antibody and the ATRX Rabbit Polyclonal Antibody to identify mutation status in patients diagnosed with brain cancer.

[Purdue University] A team of Purdue University scientists led by Dr. Shihuan Kuang has received a $2.5 million grant from the National Institutes of Health to define the role of lipid droplets in muscle stem cell function, a study with implications in both humans and livestock.

[Altamira Therapeutics, Ltd.] Altamira Therapeutics, Ltd. announced that it had filed a provisional patent application with the United States Patent and Trade Office to provide broad coverage of different KRAS mutations in human cancer treatment with nanoparticles comprising the Company’s OligoPhore™ platform and a single siRNA sequence.

[LIfT Biosciences [B3C Newswire]] LIfT BioSciences entered into a development and manufacturing partnership for N-LIfT, LIfT’s first-in-class neutrophil progenitor based Leukocyte Infusion Therapy for the treatment of various cancer indications, including Pancreatic Cancer, Lung Cancer, and other solid tumors.

[Moderna, Inc. (Targeted Oncology)] Positive data from the phase IIb KEYNOTE-942 trial led to the FDA to grant a breakthrough therapy designation to mRNA-4157/V940 in combination with pembrolizumab for the adjuvant treatment of patients with high-risk melanoma following complete resection, according to Moderna, Inc.